Connect with us

Media & Technology

The Powerful Run on CyGraph Cybersecurity Platform Operator Visium Technologies Inc (OTCMKTS: VISM)

Published

on

Visium Technologies Inc (OTCMKTS: VISM) is making a powerful run up the charts on a massive surge of volume and steady accumulation by investors. The stock eclipsed its October highs and a penny on $3 million in dollar volume and is showing strong support at these new price levels.

MIcrocapdaily reported on VISM back in October after the Company filed an 8k reporting it has paid in full two convertible notes that were plaguing the stock. At the same time, the CEO of the Company starting buying up blocks of stock on the open market according to the filed form 4’s to the tune of about 230 million shares. Visium is pink current recently filing both a 10k and a 10Q; Visium has major multi-national partners such as the George Mason Research Foundation for Cybersecurity Technology as well as Nutanix currently trading for $32 on the NASDAQ Stock Exchange.

Visium Technologies Inc (OTCMKTS: VISM) is a Virginia based company focused on providing innovative cybersecurity solutions to businesses which protect and secure the operating landscape of the enterprise and their data assets. Visium Analytics provides innovative data visualization, cybersecurity technologies and solutions to businesses to protect and secure the operating landscape of the enterprise and their data assets. The Company does this through CyGraph, its proprietary platform and application using hyper-context based mappings that deliver intuitive visualization, root cause determination and remediation.

VISM is led by CEO Mark Lucky, an investment banker and corporate executive who used to work at Axys Pharmaceuticals, Inc (NASDAQ: AXPH) a San Francisco, California-based early stage drug discovery biotech company, PriceWaterhouseCoopers, LLC, COMPASS Management and Leasing, Inc., Mindscape, Inc., The Walt Disney Company and KPMG.

VISM is in a great place for accelerated growth and it expects to see its first significant revenue from CyGraph; the cybersecurity platform that allows its users to quickly turn information into knowledge by providing comprehensive visualization and context. With CyGraph®, network operators are able to have real-time visibility of their security posture and quickly and easily identify potential threats to their assets.

Earlier this year Visium successfully developed its cloud platform to deliver CyGraph via Amazon Web Services. The Company also initiated a corporate strategy to migrate its core CyGraph platform from strictly on-premises deployments to include an AWS cloud Software as a Service solution (SaaS). Visium plans to integrate a GraphBLAS engine into its CyGraph® platform. GraphBLAS is an API specification that defines standard building blocks for graph algorithms in the language of linear algebra.

To Find out the inside Scoop on VISM Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

VISM

The myriad of real-time use cases that will benefit from this new CyGraph® capability includes solution recommendations, data exploitation threat ID, and root cause determination. The GraphBLAS integrations with CyGraph® also enables enhanced Machine Learning (ML) results, by leveraging linear algebra-driven algorithms. With this capability, CyGraph® will be able to predict and rapidly determine exploitation potentials before they actually impact an organization.

Visium’s CyGraph® is now available as a cloud-based security platform through Amazon Web Services. Contact us now for a product demo and schedule your deployment of Cygraph within our fully managed AWS platform to start analyzing your data vulnerabilities like you have never seen before. The real-time security visualization engine allows users to quickly and intelligently proceed from information, to insight, to action. Cygraph® is a system that overlays context to improve network security posture, maintain situational awareness in the face of cyberattacks, and focuses on protection of business-critical assets.

On December 18 VISM commented on the recent SolarWinds cyber hack event. SolarWinds recently acknowledged that hackers had inserted malware into a service that provided software updates for its Orion platform, a platform that is broadly used across the U.S. federal government and Fortune 500 firms to monitor the health of their IT networks, and affecting more than 18,000 customers.

Mark Lucky, Visium’s Chief Executive Officer, commented, “This cyber event highlights the fact that the best cybersecurity tools aren’t always effective, and also highlights the value proposition of CyGraph as a critical cybersecurity platform. CyGraph provides understandable awareness of threats. Our TrueContextTM feature connects the dots in a human readable and understandable way. This feature is lacking with most cyber tools today. There’s a lot of data being collected and analyzed, but it is a herculean effort to relate events to problems through traditional data-mining and analysis. This is a key factor that contributes to the continued occurrence of major cyber compromises, even with the tools that are supposed to be protecting the kingdom. It proves the point that analyzing data without proper context can lead to undetected vulnerabilities. CyGraph’s forensic capabilities could have been used to identify potential vulnerabilities in SolarWinds Orion Products and attached networks. CyGraph’s TrueContextTM provides for timely risk mitigation and solutions to cyber events. The CyGraph platform provides visualization of an Enterprise’s infrastructure, assets and data relationships, so that near real-time decisions can be understood and made to protect the digital and connected ecosystem, without weeks of data-mining. Our platform could have rapidly connected the dots, through TrueContextTM, and provided alerts for the recent cyber compromises experienced by the U.S. Government, well-known industry vendors, and their respective customers. In addition, CyGraph’s forensics capability can be used to identify additional potential vulnerabilities and root causes, adding significant value to support ongoing investigations”.

For more on VISM subscribe Right Now!

VISM is making a powerful run up the charts on a massive surge of volume and steady accumulation by investors. The stock eclipsed its October highs and a penny on $3 million in dollar volume and is showing strong support at these new price levels. Microcapdaily reported on VISM back in October after the Company filed an 8k reporting it has paid in full two convertible notes that were plaguing the stock. At the same time, the CEO of the Company starting buying up blocks of stock on the open market according to the filed form 4’s to the tune of about 230 million shares. Visium is pink current recently filing both a 10k and a 10Q; Visium has major multi-national partners such as the George Mason Research Foundation for Cybersecurity Technology as well as Nutanix currently trading for $32 on the NASDAQ Stock Exchange. We will be updating on VISM when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with VISM.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in VISM either long or short and we have not been compensated for this article.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Featured

LAVA Therapeutics (NASDAQ: LVTX) Gammabody™ Platform Gains Momentum

Published

on

LAVA Therapeutics N.V. (NASDAQ: LVTX) shares soared 106% as the company announced that Janssen Biotech, Inc. chose a lead candidate.

LAVA Therapeutics N.V. (NASDAQ: LVTX) shares soared 106% as the company announced that Janssen Biotech, Inc., a part of the Janssen Pharmaceutical Companies of Johnson & Johnson, chose a lead candidate aimed at an undisclosed tumor-associated antigen for further development towards clinical settings.

GAMMABODY™ PLATFORM

LAVA primarily focuses on revolutionizing cancer therapy by developing its Gammabody™ platform. This platform enables them to create bispecific gamma delta T cell engagers that can activate a specific subset of gamma-delta T cells called Vγ9Vδ2 (Vgamma9 Vdelta2) T cells. By utilizing this approach, they aim to enhance the natural recognition of tumors, guide Vγ9Vδ2 T cells to target the tumor cells directly and trigger a cascade of immune responses.

To Discover the Inside Scoop on LVTX, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

What sets their Gammabody™ drug candidates apart is their exceptional performance and safety profiles observed in preclinical studies. Compared to other bispecific T cell engager approaches, their candidates have demonstrated superior efficacy and preferred targeting tumor cells. This targeted approach has the potential to minimize toxicity in healthy tissues.

In May 2020, LAVA entered into a research collaboration and license agreement with Janssen, a subsidiary of the Janssen Pharmaceutical Companies of Johnson & Johnson. This collaboration aimed to discover and develop novel bispecific antibody-based gamma delta T cell engagers for cancer treatment. The agreement was facilitated by Johnson & Johnson Innovation, emphasizing their commitment to fostering innovation in the field.

As part of the collaboration, LAVA had the opportunity to receive potential milestone payments and royalties based on the successful development, regulatory approvals, and commercialization of the candidates. This incentivized LAVA to actively pursue the discovery and advancement of promising lead candidates. 

The collaboration represents a remarkable milestone many early-stage biotech companies aspire to achieve. Partnering with a program brings numerous benefits, including reduced risk of dilution through milestone payments as the trials advance and streamlined commercialization once the product receives approval.

Under the terms of the agreement, Janssen will assume responsibility for the selected candidate’s future clinical development, manufacturing, and commercialization. This includes bearing the costs and expenses associated with these activities.

Stephen Hurly, LAVA Therapeutics’s president and chief executive officer, expressed satisfaction with Janssen’s selection of a lead candidate for clinical studies. He emphasized LAVA’s pioneering role in developing gamma-delta bispecific antibodies through their proprietary Gammabody platform. This platform and LAVA’s extensive expertise in bispecific antibody development position them at the forefront of advancing novel therapies for cancer patients.

In summary, LAVA Therapeutics’ collaboration with Janssen has reached a significant milestone in selecting a lead candidate for further development toward clinical studies. This progress underscores LAVA’s dedication to leveraging its Gammabody platform and expertise in bispecific antibody development to revolutionize cancer treatment.

We will update you on LVTX when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Continue Reading

Featured

Onfolio Holdings (NASDAQ: ONFO) Unleashing the Power of AI

Published

on

Onfolio Holdings Inc (NASDAQ: ONFO), a technology services company, has recently introduced an advanced generative AI search function for its subsidiary, MightyDeals.com.

Onfolio Holdings Inc (NASDAQ: ONFO), a technology services company, has recently introduced an advanced generative AI search function for its subsidiary, MightyDeals.com. The implementation of this innovative AI tool, powered by chatGPT-style Large Language Models (LLMs), has resulted in a surge of 105% in the company’s stock price and sparked tons of investor interest. The company has a 3.28M float and, at the time of writing, has traded 20x that amount, with a colossal 60M shares exchanging hands.

Revolutionizing User Experience and Driving Stock Surge

With the integration of AI search on MightyDeals.com, customers can now use natural language to describe the products they seek, simplifying the buying process. The AI tool utilizes contextual understanding and description analysis of hundreds of active deals to generate instant search results based on users’ queries. By enhancing the user experience, Onfolio Holdings anticipates increased user return rates, higher site interaction rates, and elevated revenues for MightyDeals.com. This groundbreaking development has attracted positive attention, significantly increasing Onfolio Holdings’ stock price.

To Discover the Inside Scoop on ONFO, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Evaluating Financial Performance

While the stock surge indicates investor enthusiasm, assessing Onfolio Holdings’ financial performance is crucial for comprehensive investment analysis. The positive earnings growth of +44.44% and revenue growth of +22.74% contribute to the company’s optimistic outlook. However, investors should be cautious of the negative net profit margin of -190.75% and the lack of available price/book ratio data. Monitoring the company’s financial performance leading up to the next reporting date on August 30, 2023, is advised to understand its profitability and overall stability better.

Investment Outlook and Future Prospects

Considering the stock surge and optimistic price forecasts, Onfolio Holdings has promising prospects. Analysts offer a median target price of $3.00 for the company’s stock, signaling an expectation of significant growth within the next 12 months. However, it is essential to note that Onfolio Holdings operates at a loss. Investors should thoroughly evaluate the company’s long-term growth potential and weigh the potential returns against the inherent risks before making investment decisions.

About MightyDeals.com

Mighty Deals is a free daily deals website aimed at creative professionals focusing on products and services for web designers and developers. The site offers fantastic deals on quality fonts, templates, apps, add-ons, plug-ins, ebooks, icons, and more. The site provides discounts on packages which usually range between 50%-97% off but are only available for a limited time. MightyDeals.com boasts an exceptional return rate from its users and is one of Onfolio Holdings’ highest revenue-generating subsidiaries.

About Onfolio Holdings Inc.

Onfolio acquires and manages a diversified portfolio of online businesses across a broad range of verticals, each with a niche content focus and brand identity. Onfolio acquires firms that meet its investment criteria, being that such businesses operate in sectors with long-term growth opportunities, have positive and stable cash flows, face minimal threats of technological or competitive obsolescence, and can be managed by our existing team or have strong management teams largely in place. The Company excels at finding acquisition opportunities where the seller has not fully optimized their business. Onfolio’s experience and skillset allow it to add increased value to these existing businesses.

Conclusion

Onfolio Holdings’ introduction of the generative AI search function for MightyDeals.com has increased the company’s stock price, reflecting the market’s positive response to this innovative technology. The enhanced user experience and the potential for increased revenues have positioned Onfolio Holdings as a leader in the tech industry. However, investors must carefully consider the company’s financial performance and evaluate its long-term growth potential before making investment decisions. Monitoring the company’s performance to the next reporting date will provide valuable insights into its financial health and stability.

We will update you on ONFO when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Image by James from Pixabay

Continue Reading

Featured

Enveric Biosciences (NASDAQ: ENVB) Pioneering the Future of Anxiety Disorder Treatment

Published

on

Enveric Biosciences, Inc. (NASDAQ: ENVB) shares surged 78% this morning upon approval of some fantastic news.

Enveric Biosciences, Inc. (NASDAQ: ENVB) shares surged 78% this morning upon approval of some fantastic news. The United States Patent and Trademark Office has granted them a notice of allowance for their patent application concerning a groundbreaking chemical compound called EB-373. This compound is being developed to address the treatment of anxiety disorders.

The forthcoming patent, titled “C4-Carbonothioate-Substituted Tryptamine Derivatives and Methods of Using,” encompasses claims for the composition of matter of a family of revolutionary prodrug derivatives of psilocin. Enveric’s lead product candidate, EB-373, stands out among these derivatives. A Notice of Allowance signifies that the USPTO has determined that a patent should be granted based on the submitted application.

To Discover the Inside Scoop on ENVB, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Enveric’s commitment to innovation extends beyond EB-373. They have also submitted additional patent applications to the USPTO, exploring psilocin prodrugs with unique crystalline molecular structures. Moreover, they have taken proactive steps to pursue global coverage of the EVM201 and EVM301 Series through companion Patent Cooperation Treaty and non-US national patent applications. Encouragingly, positive International Search Reports and written opinions have been received under the Patent Cooperation Treaty for most of these applications.

Joseph Tucker, Ph.D., Enveric’s director and CEO, underlined the significance of the USPTO’s favorable decision concerning their lead candidate, EB-373. He highlighted the innovative designs of their psilocin prodrugs within the EVM201 series, differentiating them from conventional counterparts like psilocybin. These novel designs hold the potential to deliver more rapid therapeutic effects, precise control, and reduced gastrointestinal side effects. Tucker emphasized that securing a robust intellectual property portfolio for their new chemical entity prodrugs is pivotal to Enveric’s value proposition and integral to their business strategy of developing cutting-edge small-molecule therapeutics to address mental health disorders.

We will update you on ENVB when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Image by Gino Crescoli from Pixabay

Continue Reading

Trending

© All rights reserved.

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.